Plastic and reconstructive surgery · 2025
Impact of Lipoabdominoplasty and Rectus Diastasis Repair on Benzodiazepine Usage in Patients with Depression and Anxiety: A Prospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tambasco Damiano, Scarabosio Anna, Tomaselli Federica, Cavaliere Annachiara, Ievoli Riccardo, Nele Gisella, Albanese Roberta
Аннотация
BACKGROUND: Lipoabdominoplasty, primarily sought for cosmetic enhancement, has shown potential benefits beyond physical transformation. Emerging evidence suggests that aesthetic procedures may positively affect mental health by improving body image and self-esteem. This study aims to assess the impact of lipoabdominoplasty on pharmacologic therapy (ie, benzodiazepines) use in patients with preexisting depression or anxiety disorders.
METHODS: This prospective cohort study included 69 patients who underwent lipoabdominoplasty. All patients were taking benzodiazepines before surgery, with dosage frequency recorded. Follow-up assessments were conducted postoperatively to document changes in drug use and evaluate mental health improvements using validated scales, including the BODY-Q.
RESULTS: A significant reduction in benzodiazepine use was observed postoperatively. At follow-up, 17% of patients discontinued medication, and 61% required a lower dosage ( P < 0.05). Complications occurred in 16% of cases, including seroma ( n = 6), infection ( n = 2), hematoma ( n = 2), and necrosis ( n = 1); 1 patient required reintervention. BODY-Q scores demonstrated significant improvements in body image and self-esteem.
CONCLUSIONS: Lipoabdominoplasty may contribute to reduced drug use, likely driven by improvements in body image and psychologic well-being. These findings underscore the potential of aesthetic surgery to enhance mental health in patients with depression or anxiety, offering an integrated holistic care approach.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
METHODS: This prospective cohort study included 69 patients who underwent lipoabdominoplasty. All patients were taking benzodiazepines before surgery, with dosage frequency recorded. Follow-up assessments were conducted postoperatively to document changes in drug use and evaluate mental health improvements using validated scales, including the BODY-Q.
RESULTS: A significant reduction in benzodiazepine use was observed postoperatively. At follow-up, 17% of patients discontinued medication, and 61% required a lower dosage ( P < 0.05). Complications occurred in 16% of cases, including seroma ( n = 6), infection ( n = 2), hematoma ( n = 2), and necrosis ( n = 1); 1 patient required reintervention. BODY-Q scores demonstrated significant improvements in body image and self-esteem.
CONCLUSIONS: Lipoabdominoplasty may contribute to reduced drug use, likely driven by improvements in body image and psychologic well-being. These findings underscore the potential of aesthetic surgery to enhance mental health in patients with depression or anxiety, offering an integrated holistic care approach.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.